Metabolic Engineering of Cancer for Selective Immunotargeting

描述（由申请人提供）：用于选择性免疫靶向的癌症代谢工程癌症是最常见和致命的疾病之一，并且通常难以治愈。在探索用于癌症治疗的不同策略中，用癌症疫苗或癌症靶向抗体治疗癌症患者特别有吸引力，因为人类免疫系统可以非常有效和选择性地消除人体中的肿瘤。在用于患者免疫或抗体制备的癌症疫苗的开发中，由癌细胞表达的异常聚糖（称为肿瘤相关碳水化合物抗原（TACA））是有价值的分子靶标，因为它们在癌细胞表面上是丰富的、暴露的和保守的。然而，问题是TACA通常免疫原性差或被患者的免疫系统耐受，这严重阻碍了基于TACA的功能性癌症疫苗或免疫疗法的递送。 为了解决这个问题并开发有效的癌症治疗方法，提出了一种新的免疫策略。首先，用由非天然TACA衍生物制成的疫苗免疫动物（或患者）以引发特异性免疫应答。接下来，用类似修饰的单糖处理动物，以生物工程肿瘤细胞表达非天然TACA衍生物（癌细胞糖工程）。然后，经过训练的免疫系统将特异性地识别并杀死糖工程肿瘤。新的免疫疗法也可以用TACA衍生物特异性抗体而不是疫苗来实现。为了使该策略发挥作用，它必须满足两个条件，即，可用于患者免疫或抗体制备的有效疫苗和癌细胞糖工程的有效方法。已经证明，后者可以利用灵活的聚糖生物合成途径。为了产生有效和可靠的基于TACA的疫苗，本文提出了一种新的疫苗策略，即将TACA连接到细菌单磷酰脂质A（MPLA）。假设MPLA可以作为一种强大的疫苗载体和内置佐剂，以配制完全合成的、自佐剂的、结构确定的、易于重现的和稳健的糖缀合物疫苗。该提案旨在：（1）研究MPLA的结构-活性关系并鉴定新的有效疫苗载体和佐剂，（2）制备和研究TACA-MPLA缀合物的免疫学性质并鉴定用于癌症免疫治疗的合适疫苗，和（3）使用新的TACA-MPLA缀合物作为通过上述治疗策略的癌症如黑素瘤和乳腺癌或结肠癌的主动和被动免疫治疗的疫苗。 本项目的创新之一是将MPLA作为载体和佐剂用于全合成自佐剂碳水化合物疫苗的开发和相关研究。另一项创新是将MPLA结合疫苗与细胞糖工程结合用于癌症治疗。这种组合将解决TACA的免疫耐受问题，这是癌症免疫学的核心问题，并有助于开发各种肿瘤的功能性治疗方法。新的疫苗策略也将适用于其他疫苗设计。因此，这两种策略应该是广泛有用的，这个研究计划应该具有普遍意义，并对癌症研究产生广泛的影响。

DESCRIPTION (provided by applicant): Metabolic Engineering of Cancer for Selective Immunotargeting Cancer is one of the most common and fatal diseases and, in general, it is difficult to cure. Among the different strategies probed for cancer therapy, treating cancer patients with cancer vaccines or cancer-targeting antibodies is especially attractive as the human immune system can be extremely effective and selective to eliminate tumors in the human body. In the development of cancer vaccines used for patient immunization or antibody preparation, the abnormal glycans expressed by cancer cells, called tumor-associated carbohydrate antigens (TACAs), are valuable molecular targets, as they are abundant, exposed, and conserved on the cancer cell surface. However, the problem is that TACAs are usually poorly immunogenic or tolerated by the patients' immune system, which has severely hindered the delivery of functional TACA-based cancer vaccines or immunotherapies. To address the problem and develop effective cancer cures, a new immunotherapeutic strategy was proposed. First, animals (or patients) are immunized with a vaccine made of an unnatural TACA derivative to elicit a specific immune response. Next, the animals are treated with a similarly modified monosaccharide to bioengineer tumor cell expression of the unnatural TACA derivative (cancer cell glycoengineering). Then, the trained immune system will specifically recognize and kill the glycoengineered tumors. The new immunotherapy can also be realized with a TACA derivative-specific antibody, instead of a vaccine, for the treatment. For the strategy to work, it has to mee two conditions, namely, a potent vaccine that can be used for patient immunization or antibody preparation and an effective method for cancer cell glycoengineering. It has been proved that the latter can exploit the flexible biosynthetic pathways for glycans. To create potent and reliabl TACA-based vaccines, a new vaccine strategy is proposed here, namely, to have TACAs linked to a bacterial monophosphoryl lipid A (MPLA). The hypothesis is that MPLA can act as a powerful vaccine carrier and built-in adjuvant to formulate fully synthetic, self-adjuvanting, structurally defined, readily reproducible, and robust glycoconjugate vaccines. This proposal aims to: (1) study the structure-activity relationship of MPLAs and identify new, potent vaccine carriers and adjuvants, (2) prepare and study the immunological properties of TACA-MPLA conjugates and identify the proper vaccines for cancer immunotherapy, and (3) use the new TACA-MPLA conjugates as vaccines for active and passive immunotherapy of cancer such as melanoma and breast or colon cancer by the above therapeutic strategy. One innovation of this project is the use of MPLA as a carrier and adjuvant for fully synthetic self-adjuvanting carbohydrate vaccine development and related studies. Another innovation is the combination MPLA conjugate vaccine with cell glycoengineering for cancer therapy. This combination will solve the immunotolerance problem of TACAs, a central issue in cancer immunology, and help develop functional cures for various tumors. The new vaccine strategy will be applicable to other vaccine design as well. Thus, both strategies should be widely useful, and this research program should be of general significance and have a broad impact on cancer research.